Table 2.
Clinical Characteristics of HIV Patients on Dolutegravir Based Regimen at DRH 2020
| Previous Regimen | N | % |
|---|---|---|
| TDF-3TC-EFV | 175 | 50.1 |
| AZT-3TC-NVP | 67 | 19.2 |
| TDF-3TC-NVP | 53 | 15.2 |
| AZT-3 TC-EFV | 46 | 13.2 |
| Others* | 8 | 2.3 |
| Current regimen | N | % |
| TDF-3TC-DTG | 349 | 100 |
| Co-morbidity | ||
| None | 312 | 89.4 |
| Yes | 37 | 10.6 |
| Opportunistic infections | 13 | % |
| Tuberculosis | 7 | 53.8 |
| Meningitis | 2 | 15.4 |
| Others** | 4 | 30.8 |
| Non-OI co-morbidity | 24 | % |
| Hypertension | 14 | 58.3 |
| Diabetes | 7 | 29.2 |
| Others*** | 3 | 12.5 |
| Concurrent medications with DTG | N (37) | |
| Isoniazid | 7 | 18.9 |
| Hydrochlorothiazide | 8 | 21.6 |
| Nifedipine | 4 | 10.8 |
| Metformin | 4 | 10.8 |
| Insulin | 3 | 8.1 |
| Others**** | 11 | 29.8 |
Notes: *ABC-3TC-EFV, ABC-3TC-NVP, **Toxoplasmosis, PCP, Oral candidacies, *** Pneumonia, PUD, ****Amoxicillin and clavulanate potassium, Metronidazole, Tramadol, Cotrimoxazole, Cimetidine, Omeprazole, Fluconazole, Pyridoxine, Enalapril, ceftriaxone.